raltitrexed 112887 68 0

Raltitrexed (112887-68-0) Raltitrexed is an anti-tumor pharmaceutical agent specifically developed for the treatment of advanced colorectal cancer. As a highly selective inhibitor of thymidylate synthase (TS), it targets the key enzyme responsible for the biochemical conversion of dUMP to dTMP. The compound enters cells via the reduced folate/methotrexate cell membrane carrier and is converted to polyglutamate species by folylpolyglutamate synthase within 4 hours, where it